Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -15,19 +15,8 @@
15	15	(((
16	16	= What is this about and what can I find here? =
17	17
18		-= **Overview** =
	18	+== **Overview** ==
19	19
20		-
21		-The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient.
22		-
23		-This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**.
24		-
25		-The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**.
26		-
27		-=== **Project Aim** ===
28		-
29		-The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**.
30		-
31	31	The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
32	32
33	33	* **Axis 1**: Etiology (genetic or other causes of diseases).
...	...	@@ -34,6 +34,10 @@
34	34	* **Axis 2**: Molecular Markers (biomarkers).
35	35	* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
36	36
	26	+
	27	+[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
	28	+
	29	+
37	37	This methodology enables:
38	38
39	39	* Greater precision in diagnosis.
...	...	@@ -40,22 +40,10 @@
40	40	* Integration of incomplete datasets using AI-driven probabilistic modeling.
41	41	* Stratification of patients for personalized treatment.
42	42
43		-== **The Role of AI-Powered Annotation** ==
44		-
45		-To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which:
46		-
47		-* **Assigns structured metadata tags** to diagnostic features.
48		-* **Provides real-time contextual explanations** for AI-based classifications.
49		-* **Tracks longitudinal disease progression** using timestamped AI annotations.
50		-* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis).
51		-* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO).
52		-
53	53	== **The case of neurodegenerative diseases** ==
54	54
55	55	There have been described these 3 diagnostic axes:
56	56
57		-[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
58		-
59	59	* (((
60	60	**Axis 1: Etiology**
61	61
...	...	@@ -85,6 +85,10 @@
85	85	* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
86	86	* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
87	87
	69	+== Who has access? ==
	70	+
	71	+We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
	72	+
88	88	== How to Contribute ==
89	89
90	90	* Access the `/docs` folder for guidelines.
...	...	@@ -96,17 +96,9 @@
96	96	* Develop interpretable AI models for diagnosis and progression tracking.
97	97	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
98	98	* Foster collaboration among neuroscientists, AI researchers, and clinicians.
99		-
100		-== Who has access? ==
101		-
102		-We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
103	103	)))
104	104
105	105
106		-
107		-
108		-
109		-
110	110	(% class="col-xs-12 col-sm-4" %)
111	111	(((
112	112	{{box title="**Contents**"}}